Kodiak Sciences Inc (KOD) Stock Price, Quote & News

Company Profile

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degenerati...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 281 0850

Website: kodiak.com

Address:

1200 Page Mill Road, Palo Alto, United States

SweepCastApp Oct. 4 at 4:41 AM

$KOD: Unusual Options Activity Alerted CALL flow observed 200x contracts at Strike price of $15 Exp on 12/19/2025 with Premium of $83K and showing BEARISH Sentiment

0 · Reply

Stekli27 Oct. 3 at 2:56 PM

$KOD $NRSN As I said before, I’m not changing my mind. Already made 16k+ since April with Kodiak and now holding 10k shares of $NRSN – for me it’s a must have. Risk is there, but the upside is even bigger. It’s a coin flip, and I’m willing to take it. Cheers

0 · Reply

Cmte6 Oct. 2 at 7:37 PM

$KOD gonna battle chop at this area for next move up. $12.95 big weekly breakout.

1 · Reply

Snackdaddy Oct. 2 at 7:26 PM

$KOD solid beating today. been loading here heavy for a flip I hope!

0 · Reply

Rider_on_the_Stonk Oct. 2 at 4:07 PM

$KOD we stuck at this $15 ish level? I figured this would dip a little more.

1 · Reply

Stekli27 Oct. 2 at 12:35 PM

$KOD

1 · Reply

Cutlass Sep. 30 at 7:14 PM

$KOD 📈

0 · Reply

buylowandwait Sep. 30 at 7:07 PM

$KOD

0 · Reply

highnihilism Sep. 30 at 10:12 AM

$LZ Legalzoom: 48 trades, $38K vs $104K avg (0.36x). $37K calls / $0.7K puts. $KOD Kodiak Sciences: 69 trades, $62K vs $45K avg (1.37x). $37K calls / $25K puts. $ARCC Ares Capital: 299 trades, $62K vs $331K avg (0.19x). $37K calls / $25K puts. $PRCT Procept Biorobotics: 195 trades, $381K vs $165K avg (2.30x). $37K calls / $344K puts.

0 · Reply

SassyStonks Sep. 29 at 4:29 PM

$KOD omg what trash

1 · Reply

New data for Kodiak's KSI-101 from the APEX study reinforce its clinically meaningful vision gains and rapid retinal drying in macular edema secondary to inflammation (MESI)

Sep 2, 2025, 8:00 AM EDT - 4 weeks ago

Kodiak Sciences to Participate in Upcoming Scientific Conferences Highlighting KSI-101 in Patients with Macular Edema Secondary to Inflammation (MESI)

Aug 27, 2025, 10:40 AM EDT - 5 weeks ago

Harbour BioMed Reports 2025 Interim Results

Aug 27, 2025, 6:54 AM EDT - 5 weeks ago

Jim Cramer: Kodiak Sciences Is A 'Pure Spec' Stock, Recommends Buying This Utilities Stock

Aug 19, 2025, 2:18 PM EDT - 6 weeks ago

Kodiak Sciences to Present at American Chemical Society Fall 2025

Aug 13, 2025, 4:00 PM EDT - 7 weeks ago

Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2025 Financial Results

Jul 10, 2025, 8:00 AM EDT - 3 months ago

Kodiak Sciences to Host Investor R&D Day on July 16, 2025

Jun 25, 2025, 4:45 PM EDT - 3 months ago

Kodiak Sciences to Present KSI-101 Highlights at 2025 Congress of the International Ocular Inflammation Society

May 29, 2025, 9:32 PM EDT - 4 months ago

Kodiak Sciences to Present at 2025 Jefferies Global Healthcare Conference

May 14, 2025, 4:15 PM EDT - 5 months ago

Kodiak Sciences Announces Recent Business Highlights and First Quarter 2025 Financial Results

May 1, 2025, 11:43 PM EDT - 5 months ago

Kodiak Sciences Data at ARVO 2025 Highlight Power and Versatility of ABC Platform in Addressing Complex Multifactorial Ocular Diseases

Mar 27, 2025, 4:01 PM EDT - 6 months ago

Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

Mar 10, 2025, 4:39 PM EDT - 7 months ago

Kodiak Sciences Completes Enrollment in Second Registrational Trial of Tarcocimab in Patients with Diabetic Retinopathy

Feb 23, 2025, 8:08 PM EST - 7 months ago

Kodiak Sciences: Anti-VEGF Could Win Nicely On Retinal Disorders

Feb 4, 2025, 7:30 AM EST - 8 months ago

Kodiak Sciences to Present at Glaucoma 360 New Horizons Forum 2025

Jan 7, 2025, 6:00 AM EST - 9 months ago

Kodiak Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference

Dec 9, 2024, 12:33 PM EST - 10 months ago

Eye-Disease Focused Kodiak Sciences Is A Promising 'Turnaround Story For 2025': Analyst Upgrades Stock

Nov 14, 2024, 4:01 PM EST - 11 months ago

Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2024 Financial Results

Nov 11, 2024, 6:15 AM EST - 11 months ago

Kodiak Sciences to Participate in Upcoming Investor Conferences

Oct 14, 2024, 5:35 PM EDT - 1 year ago

Kodiak Sciences to Present at Innovate Retina 2024

Sep 23, 2024, 6:00 AM EDT - 1 year ago

Kodiak Sciences to Host Investor R&D Day Today at 10:30am Eastern Time

Sep 17, 2024, 4:05 PM EDT - 1 year ago

Kodiak Sciences to Host Investor R&D Day on September 23, 2024 in New York City

Aug 14, 2024, 4:01 PM EDT - 1 year ago

Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2024 Financial Results

May 29, 2024, 4:36 PM EDT - 1 year ago

Kodiak Sciences to Present at Upcoming Investor and Clinical Conferences

May 15, 2024, 4:01 PM EDT - 1 year ago

Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results

May 13, 2024, 7:32 PM EDT - 1 year ago

Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy

May 2, 2024, 4:30 PM EDT - 1 year ago

Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform

Mar 28, 2024, 8:57 PM EDT - 1 year ago

Kodiak Sciences Inc. (KOD) Q4 2023 Earnings Call Transcript

Mar 28, 2024, 6:30 AM EDT - 1 year ago

Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

Mar 26, 2024, 6:15 AM EDT - 1 year ago

Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024

Jan 30, 2024, 6:30 AM EST - 1 year ago

Kodiak Sciences Announces Upcoming Presentation of First Time Results of KSI-501ABC Phase 1 Study at the Angiogenesis, Exudation, and Degeneration 2024 Virtual Meeting

Jan 4, 2024, 4:15 PM EST - 1 year ago

Kodiak Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Nov 21, 2023, 4:15 PM EST - 2 years ago

Kodiak Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference

Nov 14, 2023, 4:01 PM EST - 2 years ago

Kodiak Sciences Announces Third Quarter 2023 Financial Results and Recent Business Highlights

Nov 6, 2023, 5:00 AM EST - 2 years ago

Kodiak reboots tarcocimab tedromer development program following strong positive results in Phase 3 diabetic retinopathy GLOW study and following dialogue with US regulatory authorities on a regulatory pathway for BLA submission

Nov 1, 2023, 11:21 PM EDT - 2 years ago

KODIAK SCIENCES ANNOUNCES FIRST TIME PRESENTATION OF PRIMARY ENDPOINT DATA FROM TARCOCIMAB TEDROMER PHASE 3 GLOW STUDY IN PATIENTS WITH DIABETIC RETINOPATHY AT AMERICAN ACADEMY OF OPHTHALMOLOGY ANNUAL MEETING

Oct 11, 2023, 6:00 AM EDT - 2 years ago

Kodiak Sciences Announces Upcoming Presentations at the 56th Annual Scientific Meeting of the Retina Society

Sep 8, 2023, 6:00 AM EDT - 2 years ago

Kodiak Sciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

Sep 7, 2023, 6:00 AM EDT - 2 years ago

New one-year results for Kodiak's tarcocimab tedromer in the pivotal BEACON trial reinforce durability signal and demonstrate matched efficacy and comparable safety and tolerability in retinal vein occlusion

Aug 14, 2023, 4:01 PM EDT - 2 years ago

Kodiak Sciences Announces Second Quarter 2023 Financial Results and Recent Business Highlights

Jul 24, 2023, 6:38 AM EDT - 2 years ago

Kodiak Sciences scraps development of eye disorder drug

Jul 24, 2023, 6:36 AM EDT - 2 years ago

Kodiak Sciences stock plunges into record-low territory after decision to discontinue wet AMD treatment

Jul 24, 2023, 6:00 AM EDT - 2 years ago

Kodiak Sciences Announces Topline Results from its Phase 3 Studies of Tarcocimab Tedromer in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema and Provides Update on Tarcocimab Development Program

May 30, 2023, 4:15 PM EDT - 2 years ago

Kodiak Sciences to Present at Upcoming Investor Conferences

May 15, 2023, 4:01 PM EDT - 2 years ago

Kodiak Sciences Announces First Quarter 2023 Financial Results and Recent Business Highlights

Apr 21, 2023, 7:30 AM EDT - 2 years ago

Kodiak Sciences Announces Upcoming Presentations on its Product and Research Pipeline at ARVO 2023 Annual Meeting

Apr 3, 2023, 7:30 AM EDT - 2 years ago

Kodiak Sciences Expands Development Pipeline with Treatment of First Patient in Phase 1 Clinical Study of KSI-501, an Investigational Bispecific Antibody Biopolymer Conjugate for Retinal Diseases

Mar 28, 2023, 4:08 PM EDT - 2 years ago

Kodiak Sciences Announces Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

Feb 9, 2023, 7:30 AM EST - 2 years ago

Kodiak Sciences Announces Upcoming Presentation of KSI-301 (tarcocimab tedromer) Clinical Data and Antibody Biopolymer Conjugate Development Programs at the Angiogenesis, Exudation and Degeneration 2023 Virtual Meeting

SweepCastApp Oct. 4 at 4:41 AM

$KOD: Unusual Options Activity Alerted CALL flow observed 200x contracts at Strike price of $15 Exp on 12/19/2025 with Premium of $83K and showing BEARISH Sentiment

0 · Reply

Stekli27 Oct. 3 at 2:56 PM

0 · Reply

Cmte6 Oct. 2 at 7:37 PM

$KOD gonna battle chop at this area for next move up. $12.95 big weekly breakout.

1 · Reply

Snackdaddy Oct. 2 at 7:26 PM

$KOD solid beating today. been loading here heavy for a flip I hope!

0 · Reply

Rider_on_the_Stonk Oct. 2 at 4:07 PM

$KOD we stuck at this $15 ish level? I figured this would dip a little more.

1 · Reply

Stekli27 Oct. 2 at 12:35 PM

$KOD

1 · Reply

Cutlass Sep. 30 at 7:14 PM

$KOD 📈

0 · Reply

buylowandwait Sep. 30 at 7:07 PM

$KOD

0 · Reply

highnihilism Sep. 30 at 10:12 AM

0 · Reply

SassyStonks Sep. 29 at 4:29 PM

$KOD omg what trash

1 · Reply

Flipman10 Sep. 29 at 3:38 PM

$KOD Anyone here own KALA? Another Baker Brothers stock.

1 · Reply

John_Smithh Sep. 28 at 1:54 PM

$KOD All the recent excitement is about Ksi 101 but let’s not forget that the company has two more promissing drug candidates in the pipeline . I think that Kodiak is positioned for a major succes . We talk about money and stock price all the time but true deal is that those drugs can help millions of people in suffer . Good luck to all !

0 · Reply

MikeCaymanTrades Sep. 28 at 4:31 AM

https://www.youtube.com/shorts/MEgKCCvPuMY $KOD

0 · Reply

Draftcard Sep. 28 at 12:37 AM

$KOD

0 · Reply

Stekli27 Sep. 27 at 9:29 PM

$KOD

0 · Reply

StockScanners Sep. 27 at 5:53 AM

$KOD reached 19.39

0 · Reply

FE123 Sep. 26 at 2:52 PM

$KALA Bakers going to do a $200 Million Financing deal like they did with $KOD

0 · Reply

FE123 Sep. 26 at 12:47 PM

$KALA The Next $KOD to $$165!! Positive Data Coming on Monday!

1 · Reply

Snackdaddy Sep. 26 at 11:53 AM

$KOD expecting this to pull back further maybe as low as $13.50-$14

0 · Reply

SadyK189 Sep. 26 at 1:31 AM

Here is my Amazing daily Stocktwits report: $PEPG $NUAI $SPRC $ATCH $KOD PEPG: My post last night "Trending nicely on daily chart. Key support at 3.85 - 4.20. Next key level to test is 6.9 - 7.35. Currently at 5.80" It hit our desired zone. It went till 7.70 today SPRC: My post was" Getting up on hourly chart. Key support at 5.40 - 5.80. Next key level to test is 7.80 - 8.40. Currently at 6.28" It went till 8.90 afterwards NUAI My post last night "Still looking good on daily chart. Key support at 0.83 - 0.87. Next key level to test is 1.12 - 1.25. Currently at 0.97" It hit our desired zone. It went till 1.44 today ATCH My post last night "Tried to clear stiff resistance of 0.71 - 0.74 multiple times today. Currently at 0.67. It will again try to break this resistance zone to test 0.84 - 0.87 zone" It went till 0.8470 today KOD My post was "Good close of daily candle. Key support at 13.3 - 13.7. Next key level to test is 16.80 - 17.50" It went till 19.37 today

0 · Reply

Snackdaddy Sep. 25 at 8:14 PM

$KOD big sell off, went red for a second

0 · Reply

Snackdaddy Sep. 25 at 4:30 PM

$KOD good run over now this will head back to $15

0 · Reply

Market Cap	795.50M
Revenue (ttm)	0.00
Net Income (ttm)	-176.21M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	649,700
Avg Vol	817,162
Day's Range	N/A - N/A
Shares Out	52.82M
Stochastic %K	34%
Beta	2.67
Analysts	Hold
Price Target	$10.80